Ketamine Korner: Edition 5

Ketamine Korner is a bi-weekly newsletter exploring advances in ketamine therapy, originally started by Mind Pain Relief Institute Co-Founder Dr. Rohit Aiyer. 

Each edition is republished with permission from Dr. Aiyer.

Latest Research Highlight:

A 2024 meta-analysis in Translational Psychiatry pooled data from 12 studies, including 7 randomized controlled trials, to evaluate ketamine’s effect on suicidal ideation in patients with depression. The authors found that ketamine led to an approximate 55–60 percent reduction in suicidal ideation within 24 hours, with benefits that could last up to several days in many patients.

Earlier, a randomized clinical trial from Columbia University, published in the American Journal of Psychiatry in 2017, compared a single low dose of intravenous ketamine with midazolam (an active placebo) in 80 adults with major depression and clinically significant suicidal ideation. Within 24 hours, the ketamine group showed a greater reduction in suicidal thoughts than the midazolam group, and this effect was only partly explained by overall mood improvement. In some patients, clinical benefit persisted for several weeks.

Together, these findings support ketamine as a rapid-acting intervention for suicidal ideation in severe depression, particularly in closely monitored clinical settings.

A Brief History of Ketamine and Suicide Prevention:

Early Rapid-Acting Antidepressant Evidence: In 2006, a landmark trial at the U.S. National Institute of Mental Health showed that a single intravenous dose of ketamine could produce robust and rapid antidepressant effects within about two hours, lasting up to one week in treatment-resistant major depression. This work opened the door to exploring ketamine not only for mood but also for high-risk situations such as acute suicidality.

Focusing on Suicidal Ideation: By the 2010s, researchers began designing trials that specifically measured suicidal thoughts as a primary outcome. The Columbia University trial in 2017 demonstrated that ketamine could reduce suicidal ideation more than an active comparator within 24 hours, in patients who already had significant baseline suicidal thoughts.

Regulatory Milestones: In 2019, the FDA approved esketamine (Spravato) nasal spray for treatment-resistant depression. In 2020, the indication was expanded to include depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, when used in conjunction with standard of care.

This made esketamine one of the first modern treatments explicitly studied and labeled for use in patients experiencing acute suicidal symptoms, although the label also notes that its ability to prevent suicide or long-term suicidal behavior has not been established.

Ongoing Evidence: More recent clinical work, including 2024–2025 systematic reviews, continues to show that ketamine and esketamine can rapidly reduce suicidal ideation in high-risk patients, with some studies suggesting effects that may last up to a month in certain settings.

Mythbuster:

Myth: Ketamine is only for chronic, treatment-resistant depression and has no real evidence in suicidal crisis.

Reality:

• Rapid Anti-Suicidal Effects: Multiple randomized controlled trials show that ketamine can reduce suicidal thoughts within hours to one day in people with major depression and clinically significant suicidal ideation.

• Supported by Meta-Analyses: Recent systematic reviews and meta-analyses conclude that ketamine and esketamine have a moderate to large short-term effect on suicidal ideation, often observable within 24 hours of administration.

• Regulatory Recognition, With Limits: Esketamine is FDA-approved for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, but regulators explicitly state that it is not proven to prevent suicide itself and must be used within a comprehensive treatment plan.

Key Takeaway:

Ketamine is not a stand-alone suicide-prevention drug and cannot replace crisis services, safety planning, or ongoing therapy. However, in carefully supervised clinical settings, it can provide rapid, clinically meaningful relief of suicidal thoughts, creating a critical window in which deeper therapeutic work and support can take place.

As the science evolves, so does our understanding of ketamine’s place in modern psychiatry. Staying informed helps us separate fact from myth and see where the future of treatment may lead. Until next time, stay curious and engaged with the possibilities ahead.